CHAPEL HILL, N.C. — Scientists around the world have been hot on the trail of a genetic mutation closely associated with some brain cancers and leukemia since the mutation’s discovery in 2008. The hunt is now yielding fruit. In the Jan. 18…
ORLANDO – A two-drug combination is safe and active in newly diagnosed acute myeloid leukemia and myelodysplastic syndrome patients who are usually excluded from clinical trials because they have other illnesses or poor performance status -…
WINSTON-SALEM, N.C. — Thursday, Nov. 11, 2010 — Arsenic, a toxic compound with a reputation as a good tool for committing homicide, has a significant positive effect on the survival of patients with acute promyelocytic leukemia (APL), when admin…
Rapamycin, a drug approved for use in kidney transplant patients to prevent organ rejection, could also benefit patients with lupus and other autoimmune diseases as well as patients with blood cancers, such as acute myeloid leukemia, reports a team of researchers from the University of Pittsburgh and Justus-Liebig University in Giessen, Germany. Their conclusions, outlined in a paper to be published in the journal Blood and currently posted on the journal’s Web site (www.bloodjournal.org), were based on two key discoveries about rapamycin’s mechanisms.